Those following along with Argent BioPharma Limited (ASX:RGT) will no doubt be intrigued by the recent purchase of shares by Roby Zomer, Co-Founder of the company, who spent a stonking AU$1.6m on stock at an average price of AU$0.41. That purchase boosted their holding by 310%, which makes us wonder if the move was inspired by quietly confident deeply-felt optimism.

See our latest analysis for Argent BioPharma

Argent BioPharma Insider Transactions Over The Last Year

In fact, the recent purchase by Roby Zomer was the biggest purchase of Argent BioPharma shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of AU$0.43 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Argent BioPharma insider decided to buy shares at close to current prices. Roby Zomer was the only individual insider to buy during the last year.

Roby Zomer bought 5.26m shares over the last 12 months at an average price of AU$0.41. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Argent BioPharma insiders own 41% of the company, worth about AU$8.5m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Argent BioPharma Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Argent BioPharma insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Argent BioPharma. To that end, you should learn about the 6 warning signs we've spotted with Argent BioPharma (including 5 which can't be ignored).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.